3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Leukemia
2
Myelodysplastic Syndromes
1
Lymphoma
1
High Risk Myeloid Malignancies
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Interventions
Gemcitabine
97
130-nm albumin-bound paclitaxel
47
Albumin-Bound Paclitaxel
36
Oxaliplatin
27
Fluorouracil
26
Capecitabine
20
Taxes
19
Leucovorin
19
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Bevacizumab
12
fludarabine
11
Nivolumab
11
Cetuximab
11
Cisplatin
10
durvalumab
8
Radiotherapy
8
spartalizumab
7
aldesleukin
7
Erlotinib Hydrochloride
7
Drug Therapy
7
avelumab
6
Radiosurgery
6
Paclitaxel
6
irinotecan sucrosofate
5
folfirinox
5
Ipilimumab
5
Injections
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pancreatic Neoplasms
×
Transplantation Conditioning
×
Clear all
NCT07627711
2026-06-04
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled
NCT07480928
2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled